Menu Back toDA01: Current and Future Status of Drug Development in Japan, the US, and Europe under COVID-19 Pandemic

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

DA01: Current and Future Status of Drug Development in Japan, the US, and Europe under COVID-19 Pandemic

Session Chair(s)

Hironobu  Saito, PhD

Hironobu Saito, PhD

  • Corporate Officer /Head of Medical Affairs Div.
  • Daiichi Sankyo Co., Ltd., Japan
Junko  Sato, PhD

Junko Sato, PhD

  • Director, Office of International Programs
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Contact us